Skip to main content
Full access
Professional News
Published Online: 3 September 2010

DSM-5 Task Force Considers Dimensional, Severity Measures

Abstract

This article is part of a series of commentaries from members of the task force and work groups involved in developing the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
Field trials sponsored by APA's DSM-5 Task Force will examine ways that dimensional measures can help clinicians plan and monitor care of their patients. Rather than the binary “yes-no” decision required for a categorical approach to diagnosis, dimensional approaches use quantitative ratings to measure intensity, frequency, duration, severity, or other characteristics.
Interest in dimensional assessments grew early in the revision process, as a DSM-5 Research Conference on Dimensional Assessment recommended that the task force consider developing two types of measures that might be useful to clinicians. One is a set of cross-cutting items that would be of value in almost any patient, without regard to the specific disorder; the other is a recommendation for specific measures of severity that would be used for a specific disorder the clinician is managing. Both types of measures would be used initially to establish a baseline and then on follow-up to track changes.
“Cross-cutting” measures: Both the research conference and the DSM-5 Spectrum Study Group noted that some symptoms are relevant to clinical assessment and treatment even if they are not part of the criteria set for the primary disorder the individual has; that is, they cut across diagnostic boundaries, the way that blood pressure or temperature might. Having a way to track such problems as anxiety, depressed mood, substance use, or sleep problems would help clinicians in managing almost any condition, not just a specific disorder that includes the item in its criteria set.
The task force identified a range of items that might be suitable for general use for most patients in most settings. It also specified principles to guide the development of a “cross-cutting” assessment instrument, which must have the following characteristics:
○ Useful in clinical practice.
○ Brief, simple to read, and simple to evaluate.
○ Suitable for completion by the patient or an informant, rather than a clinician, whenever possible.
○ Relevant to most patients in most clinical settings.
○ Scored on a five-point rating scale, with 0 indicating absence of the problem.
In the field trials, a long list of items is being assessed, with the expectation that the list will be reduced based on results from the trials. For each item, such as depressed mood, one or two initial questions are presented to the patient. If one of these is positive, additional questions are used to characterize the item more thoroughly.
Whenever possible, these additional questions are derived from the “short form” questions developed through an initiative supported by the National Institutes of Health (NIH). This Patient-Reported Outcome Measurement Information System (PROMIS) “aims to revolutionize the way patient-reported outcome tools are selected and employed.... PROMIS aims to develop ways to measure patient-reported symptoms ... across a wide variety of chronic diseases and conditions.” (See <www.nihpromis.org>.)
PROMIS has developed assessments for a number of clinical domains that have been identified by the DSM-5 Task Force as areas on which quantitative ratings would be useful for this cross-cutting assessment. The short forms use a set of questions identified using item response theory to place an individual's response along a unidimensional continuum based on population norms. Relevant short forms that could be useful for assessing adults include the scales for depressed mood, anxiety, anger, sleep problems, and perhaps fatigue and pain impact.
At present, the PROMIS system includes child or adolescent scales for depressed mood, anxiety, and anger, and additional scales on attention are being developed. Scales are not yet well developed for the geriatric population. The task force appreciates the opportunity to work with NIH to pursue further development of the system and its implementation in clinical practice.
Severity measures: Each work group is developing recommendations to guide clinicians in rating severity of each specific disorder. The clinician will assign the severity rating, using all information available at the time of evaluation. That information may include results from a self-report rating scale (for example, the PHQ-9 for major depressive disorder).
While clinical research has generated a wide range of assessment instruments, many of these would be difficult to use in busy clinical practices. The task force hopes to produce an initial set of recommended assessment instruments that will be tested and refined over time, so measurement-based care will become feasible in any clinical setting.

Information & Authors

Information

Published In

History

Published online: 3 September 2010
Published in print: September 3, 2010

Authors

Affiliations

Jay Burke, M.D., M.P.H.
Jack Burke, M.D., M.P.H., is chair and chief of the Department of Psychiatry at the Cambridge Health Alliance and a professor of psychiatry at Harvard Medical School. Helena Kraemer, Ph.D., is a professor of psychiatry and behavioral sciences at Stanford University. David Shaffer, M.D., is the Irving Philips Professor of Child Psychiatry and a professor of pediatrics and child and adolescent psychiatry at the New York State Psychiatric Institute.
Helena C. Kraemer, Ph.D.
Jack Burke, M.D., M.P.H., is chair and chief of the Department of Psychiatry at the Cambridge Health Alliance and a professor of psychiatry at Harvard Medical School. Helena Kraemer, Ph.D., is a professor of psychiatry and behavioral sciences at Stanford University. David Shaffer, M.D., is the Irving Philips Professor of Child Psychiatry and a professor of pediatrics and child and adolescent psychiatry at the New York State Psychiatric Institute.
David Shaffer, M.D.
Jack Burke, M.D., M.P.H., is chair and chief of the Department of Psychiatry at the Cambridge Health Alliance and a professor of psychiatry at Harvard Medical School. Helena Kraemer, Ph.D., is a professor of psychiatry and behavioral sciences at Stanford University. David Shaffer, M.D., is the Irving Philips Professor of Child Psychiatry and a professor of pediatrics and child and adolescent psychiatry at the New York State Psychiatric Institute.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share